BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies

Reuters

1 hour ago

March 4 (Reuters) - CervoMed Inc CRVO.O:

CERVOMED ANNOUNCES SELECTION OF FORMULATION AND DOSING REGIMEN FOR PLANNED PHASE 3 TRIAL IN PATIENTS WITH DEMENTIA WITH LEWY BODIES
CERVOMED INC - TO INITIATE GLOBAL PHASE 3 TRIAL IN DLB IN SECOND HALF OF 2026

Source text: ID:nGNX1Jtn5D

Further company coverage: CRVO.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2616530846"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616530846\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616530846?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 20:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616530846","market":"nz","top_or_hot":-1,"title":"BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies</title></head><body><p><span>March 4 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Inc <span>CRVO.O</span>:</p><ul><li><p>CERVOMED ANNOUNCES SELECTION OF FORMULATION AND DOSING REGIMEN FOR PLANNED PHASE 3 TRIAL IN PATIENTS WITH DEMENTIA WITH LEWY BODIES</p></li><li><p>CERVOMED INC - TO INITIATE GLOBAL PHASE 3 TRIAL IN DLB IN SECOND HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNX1Jtn5D</span></p><p>Further company coverage: <span>CRVO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-04 20:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies</title></head><body><p><span>March 4 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Inc <span>CRVO.O</span>:</p><ul><li><p>CERVOMED ANNOUNCES SELECTION OF FORMULATION AND DOSING REGIMEN FOR PLANNED PHASE 3 TRIAL IN PATIENTS WITH DEMENTIA WITH LEWY BODIES</p></li><li><p>CERVOMED INC - TO INITIATE GLOBAL PHASE 3 TRIAL IN DLB IN SECOND HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNX1Jtn5D</span></p><p>Further company coverage: <span>CRVO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVO","symbol_name":"CervoMed","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA69F5X9:1","article_id":"2616530846","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616530846","pubTimestamp":1772627603,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy BodiesMarch 4 (Reuters) - CervoMed Inc CRVO.O:CERVOMED ANNOUNCES SELE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVO":"CervoMed","BK4139":"生物科技"},"translate_title":"简介-Cervomed宣布为路易体痴呆患者计划的3期试验选择配方和给药方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":0.9},"content_text":"BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy BodiesMarch 4 (Reuters) - CervoMed Inc CRVO.O:CERVOMED ANNOUNCES SELECTION OF FORMULATION AND DOSING REGIMEN FOR PLANNED PHASE 3 TRIAL IN PATIENTS WITH DEMENTIA WITH LEWY BODIESCERVOMED INC - TO INITIATE GLOBAL PHASE 3 TRIAL IN DLB IN SECOND HALF OF 2026Source text: ID:nGNX1Jtn5DFurther company coverage: CRVO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}